Dopamine D2 and D3 Receptor Occupancy in Normal Humans Treated with the Antipsychotic Drug Aripiprazole (OPC 14597): A Study Using Positron Emission Tomography and [11C]Raclopride
暂无分享,去创建一个
Gerhard Gründer | Robert F. Dannals | Hayden T. Ravert | Dean Foster Wong | D. Wong | R. Dannals | H. Ravert | K. Bizière | G. Gründer | Fuji Yokoi | Ahmet S. Dogan | F. Yokoi | A. S. Doğan | M. Stephane | Kathleen Biziere | Massoud Stephane | Ajit Suri | Steven L. Bramer | A. Suri | S. Bramer
[1] H. Ueda,et al. Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum. , 1997, European journal of pharmacology.
[2] C. Marsden,et al. Changes in rat striatal dopamine turnover and receptor activity during one years neuroleptic administration. , 1980, European journal of pharmacology.
[3] G. Sedvall,et al. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. , 1988, Archives of general psychiatry.
[4] C. Marsden,et al. Chronic neuroleptic treatment specifically alters the number of dopamine receptors in rat brain. , 1981, Life sciences.
[5] C. D. Arnett,et al. Serial [18F]N-methylspiroperidol PET studies to measure changes in antipsychotic drug D-2 receptor occupancy in schizophrenic patients , 1988, Biological Psychiatry.
[6] K. Yamada,et al. Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro -2(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland. , 1996, The Journal of pharmacology and experimental therapeutics.
[7] S. Kapur,et al. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. , 2001, The American journal of psychiatry.
[8] A. Lammertsma,et al. Simplified Reference Tissue Model for PET Receptor Studies , 1996, NeuroImage.
[9] Marc Laruelle,et al. Imaging D2 Receptor Occupancy by Endogenous Dopamine in Humans , 1997, Neuropsychopharmacology.
[10] P. Seeman,et al. Antipsychotic drug doses and neuroleptic/dopamine receptors , 1976, Nature.
[11] R. Depoortère,et al. Discriminative stimulus effects of apomorphine and 7-OH-DPAT: a potential role for dopamine D3 receptors , 1997, Psychopharmacology.
[12] C. Marsden,et al. Cerebral dopamine function in rats following withdrawal from one year of continuous neuroleptic administration. , 1980, European journal of pharmacology.
[13] D. Wong. In vivo imaging of D2 dopamine receptors in schizophrenia: the ups and downs of neuroimaging research. , 2002, Archives of general psychiatry.
[14] K. Davis,et al. Dopamine autoreceptor and postsynaptic receptor blocking potency of neuroleptics. , 1982, European journal of pharmacology.
[15] S. Snyder,et al. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. , 1976, Science.
[16] D J Brooks,et al. Comparison of Methods for Analysis of Clinical [11C]Raclopride Studies , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[17] M. Laruelle. Imaging Synaptic Neurotransmission with in Vivo Binding Competition Techniques: A Critical Review , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[18] G. Sedvall,et al. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. , 1992, Archives of general psychiatry.
[19] P.2.114 Aripiprazole, a new typical antipsychotic: Phase 2 clinical trial result , 1997, European Neuropsychopharmacology.
[20] S. Kapur,et al. High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study. , 1996, The American journal of psychiatry.
[21] M. Phelps,et al. In vivo [3H]Spiperone Binding: Evidence for Accumulation in Corpus Striatum by Agonist-Mediated Receptor Internalization , 1988, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[22] Matthias J. Müller,et al. Occupancy of striatal D2-like dopamine receptors after treatment with the sigma ligand EMD 57445, a putative atypical antipsychotic , 1999, Psychopharmacology.
[23] S. Snyder,et al. Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. , 1977, Science.
[24] H. Wetzel,et al. Roxindole, a dopamine autoreceptor agonist, in the treatment of positive and negative schizophrenic symptoms. , 1994, American Journal of Psychiatry.
[25] David R. Sibley,et al. Interactions of the Novel Antipsychotic Aripiprazole (OPC-14597) with Dopamine and Serotonin Receptor Subtypes , 1999, Neuropsychopharmacology.
[26] C. Marsden,et al. Striatal dopamine receptors become supersensitive while rats are given trifluoperazine for six months , 1979, Nature.
[27] W. Sadee,et al. Sequestration of dopamine D2 receptors depends on coexpression of G-protein-coupled receptor kinases 2 or 5. , 1999, European journal of biochemistry.
[28] T Greitz,et al. Preparation of 11C-labelled Raclopride, a new potent dopamine receptor antagonist: preliminary PET studies of cerebral dopamine receptors in the monkey. , 1985, The International journal of applied radiation and isotopes.
[29] J Delforge,et al. Concept of reaction volume in the in vivo ligand-receptor model. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[30] J. Kane,et al. Efficacy of aripiprazole in psychotic disorders: Comparison with haloperidol and placebo , 2000, Schizophrenia Research.
[31] D. Wong,et al. Effects of endogenous dopamine on kinetics of [3H]N‐methylspiperone and [3H]raclopride binding in the rat brain , 1991, Synapse.
[32] D. Sibley,et al. Agonist-induced desensitization of D2 dopamine receptors in human Y-79 retinoblastoma cells. , 1991, Molecular pharmacology.
[33] A. Gjedde,et al. Compartments and reaction volumes of brain fluid spaces: shaken, not stirred. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[34] Christer Halldin,et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: A double-blind PET study of schizophrenic patients , 1993, Biological Psychiatry.
[35] C. Marsden,et al. Effects of discontinuous drug administration on the development of dopamine receptor supersensitivity during chronic trifluoperazine or cis-flupenthixol administration to rats , 2004, Psychopharmacology.
[36] Stephen M. Rao,et al. Neural systems for reorienting visual attention when targets appear in unexpected locations , 2000, NeuroImage.
[37] S. Kapur,et al. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. , 1999, The American journal of psychiatry.
[38] H. Kung,et al. Noninvasive quantification of dopamine D2 receptors with iodine-123-IBF SPECT. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[39] S. Kapur,et al. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. , 2000, Archives of general psychiatry.
[40] J. Maloteaux,et al. Agonist-induced muscarinic cholinergic receptor internalization, recycling and degradation in cultured neuronal cells. Cellular mechanisms and role in desensitization. , 1994, Biochemical pharmacology.
[41] Albert Gjedde,et al. Quantification of Extracellular Dopamine Release in Schizophrenia and Cocaine Use by Means of TREMBLE , 1998 .
[42] L. Farde,et al. Kinetic Analysis of Central [11C]Raclopride Binding to D2-Dopamine Receptors Studied by PET—A Comparison to the Equilibrium Analysis , 1989, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[43] S. Morita,et al. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. , 1995, The Journal of pharmacology and experimental therapeutics.
[44] C. Sternini,et al. Role of agonist-dependent receptor internalization in the regulation of μ opioid receptors , 2000, Neuroscience.
[45] T. Cooper,et al. Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. , 1989, The American journal of psychiatry.
[46] C. Bohm,et al. Correction for Scattered Radiation in a Ring Detector Positron Camera by Integral Transformation of the Projections , 1983, Journal of computer assisted tomography.
[47] J. Maloteaux,et al. Trapping of labelled ligands in intact cells: a pitfall in binding studies. , 1983, Biochemical pharmacology.
[48] M. von Zastrow,et al. Distinct Dynamin-dependent and -independent Mechanisms Target Structurally Homologous Dopamine Receptors to Different Endocytic Membranes , 1999, The Journal of cell biology.
[49] S. Peroutka,et al. Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic, and histamine receptors to clinical potency. , 1980, The American journal of psychiatry.